SGH
Sivik Global Healthcare Portfolio holdings
AUM
$224M
1-Year Return
5.3%
This Quarter Return
+13.26%
1 Year Return
+5.3%
3 Year Return
+45.33%
5 Year Return
+103.79%
10 Year Return
+430.94%
AUM
$232M
AUM Growth
-$69.4M
(-23%)
Cap. Flow
-$146M
Cap. Flow
% of AUM
-62.8%
Top 10 Holdings %
Top 10 Hldgs %
36.64%
Holding
63
New
12
Increased
9
Reduced
17
Closed
25
Top Buys
| 1 |
Eli Lilly
LLY
|
$8.14M |
| 2 |
CTLT
CATALENT, INC.
CTLT
|
$7.92M |
| 3 |
Abbott
ABT
|
$7.07M |
| 4 |
Universal Health Services
UHS
|
$6.96M |
| 5 |
UnitedHealth
UNH
|
$6.86M |
Top Sells
| 1 |
Thermo Fisher Scientific
TMO
|
$38M |
| 2 |
Humana
HUM
|
$19.7M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$11.8M |
| 4 |
Smith & Nephew
SNN
|
$11.6M |
| 5 |
HRC
HILL-ROM HOLDINGS, INC.
HRC
|
$9.55M |
Sector Composition
| 1 | Healthcare | 98.4% |
| 2 | Energy | 1.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Merck
MRK
$208B
| $4.98M | 2.14% |
62,880
-26,200
| -29% | -$2.07M |
|
|
27
BioMarin Pharmaceuticals
BMRN
$10.9B
| $4.95M | 2.13% |
65,000
-155,000
| -70% | -$11.8M |
|
28
IQVIA
IQV
$30.9B
| $4.73M | 2.03% |
+30,000
| New | +$4.73M |
|
29
Encompass Health
EHC
$12.5B
| $4.22M | 1.82% |
+81,705
| New | +$4.22M |
|
30
Guardant Health
GH
$7.44B
| $3.91M | 1.68% |
+35,000
| New | +$3.91M |
|
31
Bio-Rad Laboratories Class A
BIO
$7.79B
| $3.87M | 1.66% |
+7,500
| New | +$3.87M |
|
32
Becton Dickinson
BDX
$54.6B
| $3.72M | 1.6% |
16,400
-1,806
| -10% | -$410K |
|
|
LHCG
33
DELISTED
LHC Group LLC
LHCG
| $3.72M | 1.6% |
17,500
-12,500
| -42% | -$2.66M |
|
|
AMED
34
DELISTED
Amedisys
AMED
| $3.55M | 1.53% |
15,000
-10,000
| -40% | -$2.36M |
|
35
Biogen
BIIB
$20.1B
| $3.4M | 1.46% |
12,000
-3,000
| -20% | -$851K |
|
36
Owens & Minor
OMI
$412M
| $3.14M | 1.35% |
125,000
-173,700
| -58% | -$4.36M |
|
|
NUVA
37
DELISTED
NuVasive, Inc.
NUVA
| $2.19M | 0.94% |
+45,100
| New | +$2.19M |
|
38
Select Medical
SEM
$1.6B
| $2.19M | 0.94% |
194,880
-18,560
| -9% | -$208K |
|
39
AbbVie
ABBV
$374B
| – | – |
-13,000
| Closed | -$5.87M |
|
40
Adaptive Biotechnologies
ADPT
$1.96B
| – | – |
-50,000
| Closed | -$2.42M |
|
41
Agios Pharmaceuticals
AGIO
$2.09B
| – | – |
-40,000
| Closed | -$2.14M |
|
42
Amneal Pharmaceuticals
AMRX
$2.94B
| – | – |
-600,000
| Closed | -$2.86M |
|
43
AstraZeneca
AZN
$253B
| – | – |
-60,000
| Closed | -$9.21M |
|
|
BLUE
44
DELISTED
bluebird bio
BLUE
| – | – |
-2,702
| Closed | -$2.14M |
|
45
Bristol-Myers Squibb
BMY
$94.3B
| – | – |
-60,000
| Closed | -$3.81M |
|
46
BioNTech
BNTX
$24.4B
| – | – |
-40,000
| Closed | -$2.67M |
|
47
Cardinal Health
CAH
$35.6B
| – | – |
-75,000
| Closed | -$6.46M |
|
48
Cigna
CI
$80.8B
| – | – |
-35,000
| Closed | -$6.31M |
|
49
CRISPR Therapeutics
CRSP
$4.71B
| – | – |
-30,000
| Closed | -$2.21M |
|
50
Gilead Sciences
GILD
$139B
| – | – |
-50,000
| Closed | -$3.85M |
|